✦ LIBER ✦

Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease

✍ Scribed by Susie M.D. Henley; Edward J. Wild; Nicola Z. Hobbs; Chris Frost; David G. MacManus; Roger A. Barker; Nick C. Fox; Sarah J. Tabrizi

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 305 KB
Volume: 24
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22485

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole‐brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole‐brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI‐based measures of whole‐brain atrophy may have potential as a measure of progression in HD. © 2009 Movement Disorder Society

📜 SIMILAR VOLUMES

Rate and acceleration of whole-brain atr

Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease

✍ Edward J. Wild; Susie M.D. Henley; Nicola Z. Hobbs; Chris Frost; David G. MacMan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 1 views

Huntington's disease (HD) produces progressive and ultimately widespread impairment of brain function. Neostriatal atrophy alone cannot account for whole-brain losses seen postmortem, and the mutant huntingtin protein and its neuropathologic sequelae are evident throughout the brain. Whole-brain atr

Early changes in white matter pathways o

Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease

✍ Eve M. Dumas; Simon J.A. van den Bogaard; Margot E. Ruber; Ralf Reilmann; Julie 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

## Abstract __Objectives__: To investigate the function–structure relationship of white matter within different stages of Huntington's disease (HD) using diffusion tensor imaging (DTI). __Experimental design__: From the TRACK‐HD study, an early stage HD group and a premanifest gene carrier group (P

Progression of premanifest and early Hun

Progression of premanifest and early Huntington's disease detectable after 1 year—Does TRACK-HD open the door to disease-modifying trials in HD and beyond?

✍ Ralf Reilmann 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB 👁 1 views

A controlled clinical trial of baclofen

A controlled clinical trial of baclofen as protective therapy in early huntington's disease

✍ Dr. Ira Shoulson; Charles Odoroff; David Oakes; Jill Behr; David Goldblatt; Eric 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 872 KB

HIV-1 ICD p24 antigen detection in Ugand

HIV-1 ICD p24 antigen detection in Ugandan infants: Use in early diagnosis of infection and as a marker of disease progression

✍ Laura A. Guay; David L. Hom; Sam R. Kabengera; Estelle M. Piwowar-Manning; Peter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views